Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhinovirus-induced asthma immunotherapy (Advagene)
- Development stage
- Preclinical
- Lead developer
- Advagene
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Advagene's Rhinovirus-induced asthma immunotherapy is an experimental protein-based therapeutic vaccine designed to prevent or mitigate asthma exacerbations triggered by rhinovirus infections. The therapy utilizes Advagene's proprietary LTh(αK) platform, which consists of a detoxified heat-labile enterotoxin (LT) from *Escherichia coli* that serves as a potent mucosal adjuvant and immunomodulator. By delivering rhinovirus-related antigens intranasally alongside the LTh(αK) protein, the treatment aims to modulate the mucosal immune environment in the respiratory tract, potentially shifting the immune response away from the inflammatory pathways that lead to severe asthma attacks during viral infections. As of early 2024, the candidate is in the exploration or preclinical stage of development.
- Brand names
- LT-Allergy
- Other names
- 鼻病毒誘發氣喘免疫治療Rhinovirus-induced asthma immunotherapy
02
Targets
GM1 (GM1 ganglioside)
Beyond the preview
Go deeper on Rhinovirus-induced asthma immunotherapy (Advagene).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rhinovirus-induced asthma immunotherapy (Advagene).